Archer Materials has sufficient financial resources to advance qubit processor and biochip technologies

Archer Materials is advancing its 12CQ qubit process chip for quantum computing and its lab-on-a-chip biochip technologies.

Archer Materials (ASX: AXE) ended the December 2022 quarter (Q2 FY2023) well funded with $24.3 million in cash to continue advancing its unique qubit processor and biochip technologies.

The company focuses on the further development of its 12CQ qubit process chip for quantum computing (12CQ chip) and its lab-on-a-chip biochip.

archer 12The CQ chip is being developed to enable mobile quantum computing devices.

Commenting on Archer’s activities in the second quarter of fiscal 2023, Chief Executive Greg English said the company continues to demonstrate it 12The CQ chip can be compatible with existing technologies, having used standard and commercially available metal-oxide-semiconductor (CMOS) chip technology to capture on-chip quantum information 12CQ chip at room temperature.

CMOS is the primary technology used in the design of chips for the semiconductor industry. It is commonly used to form integrated circuits in numerous and varied applications.

Archer anticipates continued use of this technology over the long term, so demonstrating “functional incorporation” with it was important 12CQ chip.

“In November, Archer, in collaboration with the École Polytechnique Fédérale de Lausanne (EPFL), used powerful supercomputers to accurately simulate Archer’s behavior 12CQ qubit material,” explained Mr. English.

The complex atomic structure of 12The CQ chip requires the “enormous power” of supercomputers for predictive modeling and realistic simulations of qubit material properties.

The results of this work confirm Archer’s unique qubit properties, including confirmation of its intrinsic metal-like character.

Mr English said the simulations will aid in the design and development of more complex equipment needed for future operations 12CQ chip technology.


When advancing his 12CQ chip technology, Archer also continues to work on his biochip.

This technology aims to integrate graphene field effect transistors (gFETs) into advanced fluidics systems to create miniaturized lab-on-a-chip device platforms for medical diagnostics.

Mr. English said the company undertook “considerable biochip development work” in the second quarter of fiscal 2023, including the manufacture of a working liquid-gated gFET.

“The transistor consists of a one-atom-thick layer of graphene that acts as an ultra-sensitive sensor, and is an exciting development to realize viable biochip technology at Archer,” he explained.

“In addition to fabricating the gFET, the Archer team developed an early prototype integrated biochip platform with automated liquid sample handling and reading.”

Mr. English added that this system will enable Archer’s team to obtain accurate, reliable, reproducible and fast data on the biochips.

added value

Archer has secured patents for its qubit processor technology in the US, China, South Korea, Japan, Hong Kong, Europe and Australia.

In developing its technologies, Archer has access to more than $1 billion worth of deep tech infrastructure and facilities.

According to Archer, it is the only ASX-listed company developing a qubit processor and among only a few in the world.